Influence of Abutment Shape on Peri-implant Marginal Bone Loss
Influence of Different Abutment Shape on Peri-implant Marginal Bone Loss: A Randomized Clinical Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46010
- Clínica Odontológica de la Universitat de Valencia, Fundación Lluis Alcanyis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any subject requiring two implants in the posterior mandible or maxilla, being at least 18 years old and able to sign an informed consent. Final patient inclusion will be made after flap elevation during the implant placement surgery to be able to confirm the presence of a vertical thickness ≥ 3mm of keratinized soft tissues.
- Bone volumes should allow the placement of implants at least 8 mm long (i.e, 10 mm bone height to the inferior alveolar nerve) and 4.2 mm wide (7 mm wide bone crest) without bone regeneration procedures.
- Patients will be grouped into: 1) non smokers; 2) light smokers (≤ 10 cigarettes/day); 3) heavy smokers (≥ 11 cigarettes/day)
Exclusion Criteria:
- Patients unable to commit to follow-up.
- General contraindications to implant surgery.
- Immuno-suppressed/immune-compromised patients.
- Patients irradiated in the head and/or neck.
- Uncontrolled diabetes.
- Pregnancy or lactation.
- Untreated periodontal disease.
- Poor oral hygiene and motivation.
- Addiction to alcohol or drugs.
- Psychiatric problems and/or unrealistic expectations.
- Patients with an acute infection (abscess) or suppuration in the site intended for implant placement.
- Patients treated or under treatment with intravenous amino-bisphosphonates.
- Patients referred only for implant placement if the follow-up cannot be done at the treatment center.
- Patients participating in other studies, if the present protocol could not be fully adhered to.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control group - Commercially available high abutments
Commercially available 2.5mm high abutments
|
Patients will be randomly selected for the commercially available high abutments option.
Two or three implants will be placed following the drilling protocol suggested by the manufacturer.
Implants will be placed 0.5mm subcrestal.
Once the implants have been placed, periapical radiographs and clinical pictures will be taken.
Implants will be uncovered 10 weeks after being placed.
After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer.
Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken.
The abutments will not be unscrewed thereafter throughout the study.
|
|
Experimental: Test group - Modified shape abutments
Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
|
Patients will be randomly selected for the modified shape abutments option.
Two or three implants will be placed following the drilling protocol suggested by the manufacturer.
Implants will be placed 0.5mm subcrestal.
Once the implants have been placed, periapical radiographs and clinical pictures will be taken.
Implants will be uncovered 10 weeks after being placed.
After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer.
Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken.
The abutments will not be unscrewed thereafter throughout the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peri-implant bone level changes
Time Frame: 12 months after implant loading
|
Assessed on digital periapical radiographs taken with the paralleling technique at delivery of crowns (implant loading) and 12 months afterwards.
|
12 months after implant loading
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant survival rate
Time Frame: 12 months after implant loading
|
% of implants in function
|
12 months after implant loading
|
|
Probing pocket depth
Time Frame: 12 months after implant loading
|
Measured in millimeters with a millimetered periodontal probe
|
12 months after implant loading
|
|
Bleeding on probing
Time Frame: 12 months after implant loading
|
Positive or negative bleeding after having probed with a millimetered periodontal probe
|
12 months after implant loading
|
|
Peri-implant soft tissue recession
Time Frame: 12 months after implant loading
|
Measured in millimeters with a millimetered periodontal probe
|
12 months after implant loading
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H1524219380739
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.